<DOC>
	<DOCNO>NCT01990534</DOCNO>
	<brief_summary>This phase 4 , single-arm , open-label , multicenter study design evaluate efficacy safety brentuximab vedotin single agent adult participant histologically confirm CD30+ relapse refractory classical Hodgkin Lymphoma receive prior stem cell transplantation ( SCT ) consider suitable SCT multiagent chemotherapy time study entry .</brief_summary>
	<brief_title>A Study Brentuximab Vedotin Participants With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description>The drug test study call brentuximab vedotin . Brentuximab vedotin test treat people relapse refractory Hodgkin Lymphoma . This study look overall response people take brentuximab vedotin . The study enrol 60 patient . Participants receive : â€¢ Brentuximab vedotin 1.8 mg/kg This multicenter trial conduct worldwide . The overall time participate study approximately 6 7 year . Participants make multiple visit clinic , contact telephone every 3 month 18 month end treatment ( EOT ) follow-up assessment overall survival every 6 month death , study closure , 5 year enrollment last participant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Each participant must meet follow inclusion criterion enrol study : 1 . Male female participant 18 year old , relapse refractory classical Hodgkin lymphoma ( HL ) , previously receive least 1 prior systemic chemotherapeutic regimen 2 . Not suitable stem cell transplantation ( SCT ) multiagent chemotherapy , accord 1 follow criterion : Disease progression within 90 day earliest date complete remission ( CR ) complete remission unconfirmed ( CRu ) end treatment multiagent chemotherapeutic regimen and/or radiotherapy Progressive disease frontline multiagent chemotherapy Disease relapse treatment least 2 chemotherapeutic regimen , include salvage treatment 3 . Bidimensional measurable disease 4 . An Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 5 . Female participant postmenopausal least 1 year screen visit , surgically sterile , agree practice 2 effective method contraception time , agree practice true abstinence . 6 . Male participant agree practice effective barrier contraception entire study treatment period 6 month last dose study drug agree practice true abstinence . 7 . Clinical laboratory value specify study protocol . Participants meet follow exclusion criterion enrol study : 1 . Previous treatment brentuximab vedotin 2 . Previously receive autologous stem cell transplantation ( ASCT ) alloSCT 3 . Known cerebral/meningeal disease , include sign symptom suggestive progressive multifocal leukoencephalopathy ( PML ) , history PML . 4 . Female participant lactate breastfeeding pregnant . 5 . Known human immunodeficiency virus ( HIV ) . 6 . Known hepatitis B surface antigen positive , know suspect active hepatitis C infection . 7 . Grade 2 high peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Additional Relevant MeSH term :</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Hodgkin</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , T-Cell</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>